Virtu Financial LLC Invests $38,000 in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Virtu Financial LLC bought a new stake in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 11,973 shares of the company’s stock, valued at approximately $38,000.

A number of other large investors also recently added to or reduced their stakes in ORGO. Assenagon Asset Management S.A. grew its holdings in Organogenesis by 54.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after buying an additional 1,035,120 shares in the last quarter. State Street Corp increased its position in Organogenesis by 0.6% in the third quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after purchasing an additional 9,090 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Organogenesis by 2.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock valued at $2,713,000 after purchasing an additional 23,675 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Organogenesis by 35.5% during the fourth quarter. Bank of New York Mellon Corp now owns 418,820 shares of the company’s stock valued at $1,340,000 after purchasing an additional 109,762 shares during the last quarter. Finally, Wellington Management Group LLP grew its stake in shares of Organogenesis by 8.0% in the 3rd quarter. Wellington Management Group LLP now owns 241,648 shares of the company’s stock worth $691,000 after buying an additional 17,842 shares in the last quarter. 49.57% of the stock is owned by hedge funds and other institutional investors.

Organogenesis Trading Down 0.9 %

Shares of ORGO opened at $4.28 on Wednesday. The company’s fifty day simple moving average is $4.25 and its 200-day simple moving average is $3.61. The company has a market cap of $542.82 million, a P/E ratio of -71.33 and a beta of 1.66. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. Organogenesis Holdings Inc. has a twelve month low of $2.17 and a twelve month high of $6.71.

Analysts Set New Price Targets

Separately, Morgan Stanley increased their price target on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th.

Insider Activity at Organogenesis

In other news, Director Michael Joseph Driscoll sold 25,000 shares of Organogenesis stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total transaction of $127,500.00. Following the completion of the sale, the director now directly owns 166,879 shares in the company, valued at approximately $851,082.90. This trade represents a 13.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 36.90% of the stock is currently owned by insiders.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.